Cyclerion Therapeutics
CYCN
67 hedge funds and large institutions have $96M invested in Cyclerion Therapeutics in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 20 closing their positions.
166% more call options, than puts
Call options by funds: $2.07M | Put options by funds: $779K
54% more capital invested
Capital invested by funds: $62.4M → $96M (+$33.6M)
0.24% less ownership
Funds ownership: 3.29% → 3.05% (-0.24%)
4% less funds holding
Funds holding: 70 → 67 (-3)
15% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 20
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$3.01M |
| 2 |
MP
MFN Partners
Boston,
Massachusetts
|
+$3.01M |
| 3 |
SPC
Slate Path Capital
New York
|
+$3.01M |
| 4 |
PVI
Pura Vida Investments
New York
|
+$1.59M |
| 5 |
Millennium Management
New York
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.91M |
| 2 |
State Street
Boston,
Massachusetts
|
-$992K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$769K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$553K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$546K |
CYCN Hedge Fund Activity: Q2 2021 in Review
67 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q2 2021, worth a combined $96M — up 54% from $62.4M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CYCN and 17 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 15 added.
The largest buyer was Artal Group, adding an estimated $3.01M. The largest seller was BlackRock, cutting an estimated $3.91M.
- 67 institutional investors held Cyclerion Therapeutics (CYCN) as of Q2 2021, down from 70 in Q1 2021.
- Funds reported $96M of Cyclerion Therapeutics stock for Q2 2021, up 54% quarter-over-quarter.
- 17 funds opened new Cyclerion Therapeutics positions in Q2 2021 and 20 closed out, a net change of -3 holders.
- The largest Cyclerion Therapeutics buyer in Q2 2021 was Artal Group, an estimated $3.01M added.
- The largest Cyclerion Therapeutics seller in Q2 2021 was BlackRock, an estimated $3.91M sold.
Based on aggregated 13F filings for Q2 2021.